Clinical trial
Phase II Study of a B7-1 Gene-Modified Autologous Tumor Cell Vaccine and…
NCT00031564 · H. Lee Moffitt Cancer Center and Research Institute, Other · Completed
Key facts
| NCT number | NCT00031564 |
|---|---|
| Title | Phase II Study of a B7-1 Gene-Modified Autologous Tumor Cell Vaccine and Systemic IL-2 |
| Official title | Phase II Study of a B7-1 Gene-Modified Autologous Tumor Cell Vaccine and Systemic IL-2 for Patients With Stage IV Renal Cell Carcinoma |
| Lead sponsor | H. Lee Moffitt Cancer Center and Research Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH Chiron Corporation Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Cancer |
| Intervention type | Biological |
| Interventions | Interleukin-2, B7-1 |
| Enrollment | 49 |
| Start date | May 1, 2000 |
| Primary completion | Jun 1, 2005 |
| Completion | Jun 1, 2012 |
| First posted | Jan 27, 2003 |
| Last update posted | Sep 27, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: